BridgeBio Pharma, Inc. operates as a commercial-stage biopharma company focused on genetic diseases, leveraging a portfolio operating model to efficiently advance numerous drug candidates. Its flagship approved therapy acoramidis (Attruby) has gained U.S. FDA approval and is marketed domestically and internationally through strategic partnerships, contributing to growing commercial traction. The company continues to push late-stage clinical assets, particularly in achondroplasia, limb-girdle muscular dystrophy, and autosomal dominant hypocalcemia, with positive Phase 3 readouts supporting upcoming regulatory submissions. However, BridgeBio’s historical financials reveal sustained operating losses and negative cash flows driven by high R&D and SG&A expenses, reflecting its growth investments amid a complex regulatory landscape. Capital structure includes convertible senior notes and royalty agreements linked to acoramidis sales, with active share repurchases suggesting management confidence. Going forward, key milestones include regulatory filings and market adoption of pipeline therapies, while risks center on manufacturing reliance and promotional compliance.